Publications by authors named "Asuncion Ballester Martinez"
Article Synopsis
- - A study evaluated the effectiveness and safety of dupilumab for treating bullous pemphigoid in elderly patients, with a focus on those who typically have other health issues that make standard treatments unsuitable.
- - The results showed that 53.4% of patients achieved complete remission within 4 weeks and 95.7% by week 52, with a significant reduction in itchiness and a dramatic decrease in the need for corticosteroids.
- - The treatment was found to be safe, with most adverse events being mild, and factors like shorter disease duration and exclusive skin involvement were linked to better treatment responses.
The focus of dermatology has increasingly shifted towards exploring new and innovative approaches [...
View Article and Find Full Text PDFMonocyte-to-High-Density Lipoprotein Ratio Is Associated with Systemic Inflammation, Insulin Resistance, and Coronary Subclinical Atherosclerosis in Psoriasis: Results from 2 Observational Cohorts.
J Invest Dermatol
September 2024
Systemic inflammation or insulin resistance drive atherosclerosis. However, they are difficult to capture for assessing cardiovascular risk in clinical settings. The monocyte-to-high-density lipoprotein ratio (MHR) is an accessible biomarker that integrates inflammatory and metabolic information and has been associated with poorer cardiovascular outcomes.
View Article and Find Full Text PDFArticle Synopsis
- Bullous pemphigoid (BP) is a common autoimmune blistering condition usually affecting older adults with various health issues, traditionally treated with corticosteroids, which have numerous side-effects.* -
- A study assessed the use of omalizumab, an IgE-targeting monoclonal antibody, for treating BP in patients who had previously used other therapies, finding that 83% of patients responded to the treatment.* -
- The results showed that omalizumab was well-tolerated with no reported side-effects, highlighting its potential as a safer and effective alternative for BP treatment compared to conventional therapies.*
Article Synopsis
- Bullous pemphigoid (BP) is the most common autoimmune blistering disease, caused by autoantibodies that target specific proteins in the skin, leading to inflammation and blister formation.
- Dipeptidyl peptidase 4 inhibitors (DPP4i) are the most frequently linked drugs to BP, potentially causing the condition through immune system changes and impaired protein breakdown.
- Other medications have been associated with BP as well, but the mechanisms are less clear, highlighting the need for more research as BP cases increase and new triggers are identified.
Psoriasis is a chronic and inflammatory disease that affects the skin and joints and is associated with multiple comorbidities and cardiovascular risk factors. Consequently, patients with psoriasis have an increased risk of cardiovascular diseases such as atherosclerosis, a chronic pathology that shares common inflammatory and immune-response mechanisms with psoriasis, including vascular inflammation and complement activation. To better understand the relationship between atherosclerosis and psoriasis, a proteomics study followed by a bioinformatics analysis was carried out, with a subsequent validation step using ELISA and western blotting.
View Article and Find Full Text PDFCardiovascular Screening Practices and Statin Prescription Habits in Patients with Psoriasis among Dermatologists, Rheumatologists and Primary Care Physicians.
Acta Derm Venereol
March 2023
Patients with psoriasis have a higher prevalence of cardiovascular risk factors. This study evaluated cardiovascular screening practices and statin prescribing habits among dermatologists, rheumatologists and primary care physicians (PCPs) through an online questionnaire, which was distributed through the Spanish scientific societies of the above-mentioned specialties. A total of 299 physicians (103 dermatologists, 94 rheumatologists and 102 PCPs) responded to the questionnaire.
View Article and Find Full Text PDF